Official and authoritative background links used for intake education.
Evidence-informed Depo-Provera review
Depo-Provera campaign information and records checklist
This campaign focuses on reported Depo-Provera or generic injectable medroxyprogesterone acetate use and a later intracranial meningioma diagnosis. Intake reviewers use product, timing, and medical records to understand each submission.
Depo-Transfer Lawsuit
Depo-Transfer, a popular contraceptive injection, has been linked to a significant risk of developing meningioma brain tumors. A March 2024 study published in the British Medical Journal found that long-term use of the drug could increase the risk of these tumors by over 5 times compared to non-users.
Pfizer, the manufacturer, failed to include warnings about this serious risk on the drug's US label, despite similar warnings being present in other countries for years. Women who have been diagnosed with brain tumors after using Depo-Transfer are now seeking justice and compensation for their injuries.
Eligibility Criteria
To participate in the Depo-Transfer litigation, potential plaintiffs generally need to meet the following criteria:
Used Depo-Transfer birth control shot (typically at least 2 injections).
Diagnosed with a meningioma or another type of brain tumor.
Did not receive a warning about the risk of brain tumors.
Evidence Required
Successful claims will need to proivde:
Proof of Use: Medical records or pharmacy records showing Depo-Transfer injections.
Proof of Injury: Medical records confirming a diagnosis of meningioma or brain tumor.
Depo-Transfer FAQs
The Depo-Transfer lawsuit alleges that Pfizer failed to warn users about the increased risk of developing meningioma brain tumors from using the contraceptive injection. Recent studies have shown a significant link between long-term use of Depo-Transfer and these tumors.
You may be eligible if you used the Depo-Transfer birth control shot (typically at least two injections), were subsequently diagnosed with a meningioma or other brain tumor, and did not receive a warning about this specific risk.
A meningioma is a type of tumor that forms on membranes that cover the brain and spinal cord just inside the skull. While often non-cancerous, they can be serious and require surgery or other treatment depending on their size and location.
Deadlines to file vary by state. However, due to the "discovery rule," you may still be able to file even if you used the drug years ago, as the link between Depo-Transfer and brain tumors was not widely known until recently. It is best to consult with a lawyer to determine your specific deadline.
The primary defendant is Pfizer Inc., the manufacturer of Depo-Transfer. Other potential defendants include authorized generic distributors like Viatris, Greenstone, LLC, and Prasco Labs.
Private case review
Depo Provera Lawsuit
Answer the questions below. Your submission is private and does not guarantee case acceptance.
Free to submitNo obligationConsent required before submission
Evidence-informed Depo-Provera review
Campaign guidance, records, and sources
Review the supporting information below before or after completing the private campaign form.
A practical checklist to help organize useful details before review.
Reviewed for intake accuracy by AMMS Compliance Team
Records and details that may help
- Prescription, injection, pharmacy, or provider records identifying the product and manufacturer when available
- Approximate first and last injection dates and total length of use
- Meningioma diagnosis records, imaging reports, pathology, and treatment timeline
- Names of prescribing providers, treatment facilities, and pharmacies
- Other hormone treatment history or medical details a reviewer may need to understand
Sources used for intake education
These official references are provided for background education only. They do not replace medical or legal advice.
- FDA 2025 Depo-Provera prescribing informationThe current FDA label describes a possible increased risk for growth of a meningioma, primarily with long-term use.
- FDA supplemental approval letterFDA approval record for adding meningioma information to warnings, counseling information, and patient materials.
- Federal court Depo-Provera MDL No. 3140Official Northern District of Florida page for the coordinated federal product-liability proceedings and current court documents.
- JPML transfer order for MDL No. 3140The Judicial Panel centralized the federal actions on February 7, 2025. The order summarizes the allegations and contested questions.
- European Medicines Agency safety reviewEMA safety review describing the meningioma signal for high-dose medroxyprogesterone, especially after prolonged use.
1. Submit the intake form
Share your contact details and answer the existing campaign-specific questions.
2. Organize supporting details
Gather the records, dates, communications, and other details listed for this campaign.
3. Intake follow-up
AMMS or an authorized intake partner may contact you for missing or clarifying details.
4. Legal review if appropriate
Qualified legal professionals decide whether a claim can move forward. AMMS does not provide legal advice or guarantee results.
Frequently asked questions
What is the current status of the Depo-Provera litigation?
Federal product-liability cases involving alleged meningioma injuries are coordinated in MDL No. 3140 in the Northern District of Florida for pretrial proceedings. Centralization does not decide whether the allegations are true or whether any individual claim qualifies.
What Depo-Provera records are helpful for intake?
Injection records, pharmacy records, prescribing-provider details, diagnosis records, imaging reports, and treatment timelines are useful for intake review.
Does the FDA label mention meningioma?
Yes. FDA-approved labeling updated in 2025 describes a possible increased risk for growth of a meningioma, primarily when the product is used for a long time. A label warning does not establish eligibility or causation for an individual claim.
Can AMMS tell me whether my medical condition was caused by Depo-Provera?
No. AMMS does not provide medical or legal causation opinions. Qualified medical and legal professionals evaluate those questions.
Related AMMS resources
AMMS Legal Intake Research TeamReviewed for intake accuracy by AMMS Compliance TeamLast reviewed: 2026-09-15
Important: AMMS provides intake and educational information. We are not providing medical or legal advice on this page, and submitting a form does not create an attorney-client relationship. Case value, eligibility, filing deadlines, and legal strategy must be reviewed by qualified professionals.